Scientists propose CDK2 enzyme as new target for cancer therapy
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
The American Journal of Managed Care13d
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Verywell Health on MSN7d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Nature4d
FDA approves TROP2-targeted antibody–drug conjugate for breast cancer
The FDA in January approved ... receptor 2 (HER2)-negative breast cancer following endocrine-based therapy and chemotherapy. It is the second TROP2-targeted antibody–drug conjugate (ADC) to ...
Hartford Business2d
FDA approves CT drugmaker’s therapy for rare cancer tumors
Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...
FiercePharma2d
Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
WebMD24d
FDA Approves New Treatment for Advanced Breast Cancer
21, 2025 -- The FDA has approved a new treatment for ... with metastatic breast cancer survive more than 5 years, highlighting the urgent need for improved tumor-targeted therapies.
HealthDay on MSN10d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...
University of California20h
Breast cancer treatment advances with light-activated ‘smart bomb’
It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...
Le Lézard8h
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the ...
Pfizer Receives Expanded FDA Approval for Cancer Treatment
The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.